Sungjae Shin

Goyang, KR 
Goyang, KR 

Overview

Sungjae Shin practices practicing medicine in Goyang, Republic of Korea.

Their clinical expertise encompasses Postmenopausal Osteoporosis, Osteoporosis, Menopause, and Osteomalacia.

They are actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 2 clinical trials.

Locations

Goyang, Republic of Korea
Other Locations
Seoul, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

17 Total Publications

Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women.
Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: June 19, 2024

Frequently Asked Questions about Sungjae Shin

Is Sungjae Shin a top-rated expert for Postmenopausal Osteoporosis?

MediFind is an objective health platform that identifies experts based on real-world data. Sungjae Shin is classified as an Experienced expert for Postmenopausal Osteoporosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sungjae Shin participate in research or clinical trials?

Yes. Sungjae Shin has published 17 articles and abstracts on conditions like Postmenopausal Osteoporosis. You can view a list of Sungjae Shin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shin's expertise for a condition
ConditionClose
        View All 9 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile